Meningioma, Neuroendocrine Tumors, Prostate Cancer, SSTR Positive Tumors, Thyroid Cancer
Conditions
Keywords
thyroid cancer, prostate cancer, neuroendocrine tumors, nuclear medecine, SSTR positive tumors, meningiomas
Brief summary
Development of a clinico-biological database allowing the provision of clinical data and corresponding biological materials to the medical and scientific community.
Detailed description
Targeted radionuclide therapy (TRT) aims at delivering ionizing radiation specifically to tumors for therapeutic purposes. Different types of radionuclides can be used to deliver the radiation: beta minus emitters less (ie Iodine-131, Lutecium-177), alpha (Actinium-225, Radium-223) or Auger (Indium-111). They will target tumor cells either by natural tropism (iodine for thyroid cancer, for example) or by coupling to a specific vector (antibody, peptides or small molecules) recognizing particular tumor targets, such as somatostatin receptors in neuroendocrine tumors and certain meningiomas (177Lu-DOTATATE, Lutathera®) or prostate specific membrane antigen (PSMA) in metastatic prostate cancers (177Lu-PSMA-617, Pluvicto®). Patients with thyroid cancer, prostate cancer, neuroendocrine tumors or SSTR positive tumours (like meningiomas) who should benefit form TRT may be included in this project. The clinical-biological database will help better understanding of the radiobiological mechanisms of action of ionizing radiations on both normal tissues and tumor cells and the psycho-oncological mechanisms involved in patients treated with TRT (only for ICM's patients). The collected data will help treatment optimization. To meet these demands, the research must then integrate databases creation open to researchers and the ongoing evaluation of the impact of projects on the health of cancer patients. Integrated research associated with quality biological research is the guarantee of medical progress. The multidisciplinary structure around collections of biological resources will enable the various actors to harmonize not only the collection but also the sharing of their data with a view to making them available for medico-scientific projects at a regional and national dimension. The Clinical Biological Database (BCB) should be used to identify and characterize new molecular markers for better diagnosis and / or treatment. It should also permit to optimize the collection of all this information, their integration and their transversal exploitation by different research disciplines (epidemiological, fundamental, translational, clinical). An ancillary study "IMMUNORIV" is associated to BCB RIV : The specific research aim is, first, to determine whether immune cell (lymphocytes and macrophages) scoring and characterization in metastatic thyroid cancer and NET samples at diagnosis predict the response to TRT. Second, a high-throughput approach will be used to determine i) the immune cell profile in blood samples from patients with NET, before and after TRT initiation, and ii) its possible correlation with the response to TRT. Third, using imaging techniques the possible correlation will be evaluated between tumor uptake/absorbed dose and response to TRT. By monitoring the immune response during TRT, the IMMUNORIV project will allow to identify immune response-related biomarkers that may be modulated to improve TRT effect.
Interventions
OTHERBiological collection
The biological collection will also include samples of blood samples collected before and during treatment.
OTHERtumor collection
Tumor collection (diagnosis) will be done for thyroid cancer and neuroencrine
Sponsors
Institut du Cancer de Montpellier - Val d'Aurelle
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥ at 18 years old, * Patient treated in the Nuclear Medicine Department for the treatment by metabolic radiotherapy, * Patient treated as part of his treatment for: * thyroid cancer, * a neuroendocrine tumor or any SSTR positive tumours (like meningiomas) receiving PRRT * prostate cancer. * Patient having accepted the complementary blood sample, * Patient having given his informed, written and express consent.
Exclusion criteria
* Patient not affiliated to a social security scheme, * Subject under tutelage, curatorship or safeguard of justice, * Patient in an emergency situation * Patient whose regular monitoring is a priori impossible for psychological, family, social or geographical reasons, * Pregnant and / or breastfeeding woman
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients who gave their consent to participate in the study | Until the study completion: 5 years | The proportion of patients who consent to participate in the study among the screened patients |
Countries
France
Contacts
CONTACTAurore MOUSSION
STUDY_CHAIREmmanuel DESHAYES, MD
Institut régional du Cancer Montpellier
Outcome results
None listed